A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Clinica chimica acta; international journal of clinical chemistry

• Publication date

  1994-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0009-8981(94)90256-9PMID 7704951
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Type IV collagenases in invasive tumors

  2005cited by this paper
• A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 8 (neutrophil collagenase) using monoclonal antibodies.

  1993cited by this paper
• Mr 92,000 Type IV Collagenase Is Increased in Plasma of Patients with Colon Cancer and Breast Cancer

  1993cited by this paper
• M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer.

  1993cited by this paper
• A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies.

  1993cited by this paper
• A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 1 (interstitial collagenase) using monoclonal antibodies.

  1993cited by this paper
• A one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases-2 using monoclonal antibodies.

  1993cited by this paper
• A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies.

  1992cited by this paper
• Human neutrophil gelatinase: A marker for circulating blood neutrophils. Purification and quantitation by enzyme linked immunosorbent assay

  1992cited by this paper
• Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma.

  1992cited by this paper
• Expression of 92 kDa phagocyte gelatinase by inflammatory and connective tissue cells.

  1992cited by this paper
• Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties.

  1992cited by this paper
• Expression of 92 kDa phagocyte gelatinase by inflammatory and connective tissue cells.

  1992cited by this paper
• Substrate specificities and activation mechanisms of matrix metalloproteinases.

  1991cited by this paper
• Human 92- and 72-kilodalton type IV collagenases are elastases.

  1991cited by this paper
• 92-kD type IV collagenase mediates invasion of human cytotrophoblasts

  1991cited by this paper
• Studies on the ability of 65-kDa and 92-kDa tumor cell gelatinases to degrade type IV collagen.

  1990cited by this paper
• Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080 tumor cells.

  1990cited by this paper
• Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases. An application for rheumatoid arthritis serum and plasma.

  1990cited by this paper
• Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development.

  1990cited by this paper
• Gelatinases of murine metastatic tumor cells.

  1989cited by this paper
• Enzyme Linked Immunosorbent Assays (ELISA) for the Quantitative Determination of Human Leukocyte Collagenase and Gelatinase

  1989cited by this paper
• SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages.

  1989cited by this paper
• Serum type IV collagen-degrading enzyme in hepatocellular carcinoma with metastasis.

  1988cited by this paper
• Ras oncogene mediated induction of a 92 kDa metalloproteinase; strong correlation with the malignant phenotype.

  1988cited by this paper
• Monoclonal antibodies to bovine collagenase inhibitor.

  1987cited by this paper
• Enzyme-labeling of antibodies and their fragments for enzyme immunoassay and immunohistochemical staining.

  1983cited by this paper
• Immunoglobulin producing hybrid cell lines

  1980cited by this paper

• ORal anticoaGulants in diAbetic and Nondiabetic patients with nOn-valvular atrial fibrillatioN (ORGANON).

  2023cites this paper
• Early Treatment of Acute Myocardial Infarction with Melatonin: Effects on MMP-9 and Adverse Cardiac Events

  2022cites this paper
• Matrix remodeling and collagen disintegration in Acute Myocardial Infarction

  2019cites this paper
• Association between matrix metalloproteinase‐9 and worsening heart failure events in patients with chronic heart failure

  2017influential citation
• Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease

  2017cites this paper
• Matrix Metalloproteinase-9 as a Marker for Plaque Rupture and a Predictor of Adverse Clinical Outcome in Patients with Acute Coronary Syndrome: An Optical Coherence Tomography Study

  2016cites this paper
• Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus

  2016cites this paper
• The effects of canrenone on inflammatory markers in patients with metabolic syndrome

  2015cites this paper
• Effect of Smoking on Metalloproteinases (MMPs) Activity in Patients with Acute Myocardial Infarction (AMI).

  2014cites this paper
• Human Papillary Thyroid Carcinomas Mediated by Membrane-Type 1 Matrix Metalloproteinase in Enhanced Production and Activation of Progelatinase A

  2013cites this paper
• Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects.

  2013cites this paper
• Methodological Considerations for Utilizing Plasma Matrix Metalloproteinase-9 as a Biomarker in Acute Vascular Syndromes

  2012cites this paper
• The Role of Heat Shock Protein 70, IgE and MMP-9 in Detecting Early Minor Myocardial Damage and Evaluating the Efficacy of Coronary Artery Bypass Grafting (CABG)

  2012cites this paper
• Serum levels of matrix metalloproteinase (MMP) 9, a risk factor for acute coronary syndrome, are reduced independently of serum MMP-3 by anti-TNF-α antibody (infliximab) therapy in patients with rheumatoid arthritis.

  2012cites this paper
• Ageing in Werner syndrome.

  2012cites this paper
• Matrix metalloproteinase-9 for the earliest stage acute coronary syndrome.

  2011cites this paper
• Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients

  2011cites this paper
• Clinicopathological Role of Serum-Derived Hyaluronan-Associated Protein (SHAP)-Hyaluronan Complex in Endometrial Cancer

  2011cites this paper
• Matrix Metalloproteinase-9 for the Earliest Stage Acute Coronary Syndrome : Comparison With High-Sensitivity Troponin T

  2011cites this paper
• Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects.

  2010cites this paper
• Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects.

  2010cites this paper
• Clinical and biochemical characteristics after intra-articular injection for the treatment of osteoarthritis of the knee: prospective randomized study of sodium hyaluronate and corticosteroid

  2010cites this paper
• Genetic polymorphism c.1562C>T of the MMP-9 is associated with macroangiopathy in type 2 diabetes mellitus.

  2010cites this paper
• Azelnidipine decreases plasma matrix metalloproteinase-9 levels after endovascular abdominal aortic aneurysm repair.

  2009cites this paper
• Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in blood as markers for early atherosclerosis in subjects with chronic periodontitis.

  2009cites this paper
• Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment.

  2009cites this paper
• Effects of long chain ω-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients

  2009cites this paper
• Effectsoflongchainω-3fatty acidsonmetalloproteinases andtheirinhibitorsincombined dyslipidemiapatients

  2009cites this paper
• Effect of a sequential training programme on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome

  2009cites this paper
• Role of serum-derived hyaluronan-associated protein-hyaluronan complex in ovarian cancer.

  2008cites this paper
• Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia.

  2008cites this paper
• Comparison of Renal and Vascular Protective Effects between Telmisartan and Amlodipine in Hypertensive Patients with Chronic Kidney Disease with Mild Renal Insufficiency

  2008cites this paper
• Heat Shock Protein 70 and IgE as Inflammatory Mediators, are Early Predictors of Myocardial Ischemia and Recovery Markers after Coronary Artery Bypass Grafting (CABG)

  2008cites this paper
• High serum matrix metalloproteinase-9 level predict increased risk of in-hospital cardiac events in patients with type 2 diabetes and ST segment elevation myocardial infarction.

  2008cites this paper
• Concentration of Matrix Metalloproteinase-9 in the Jugular Bulb during Carotid Endarterectomy Correlates with Severity of Intraoperative Cerebral Ischemia

  2008cites this paper
• Matrix metalloproteinase-2 and -9 levels in obese patients.

  2008cites this paper
• Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects.

  2007cites this paper
• Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome

  2007cites this paper
• Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months.

  2007cites this paper
• Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects

  2007cites this paper
• Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes.

  2007cites this paper
• Levels of matrix metalloproteinases-8 and -9 with simultaneous presence of periodontal pathogens in gingival crevicular fluid as well as matrix metalloproteinase-9 and cholesterol in blood.

  2006cites this paper
• Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.

  2006cites this paper
• Matrix Metalloproteinase-2, -9 and Tissue Inhibitor Metalloproteinase-1 in Patients with Hypertension Before and After Doxazosin Therapy

  2006cites this paper
• Differential glucocorticoid effects on proliferation and invasion of human trophoblast cell lines.

  2006cites this paper
• Matrixmetalloproteinasen und deren Gewebeinhibitoren unter iv-Immunglobulintherapie bei neuromuskulären Erkrankungen

  2006cites this paper
• Effect of β-Crytoxanthin on Circulating Bone Metabolic Markers : Intake of Juice (Citrus Unshiu) Supplemented with β-Cryptoxanthin Has an Effect in Menopausal Women

  2006cites this paper
• Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis

  2006cites this paper
• Elevation of plasma matrix metalloproteinase-9 in the culprit coronary artery in patients with acute myocardial infarction: clinical evidence from distal protection.

  2005cites this paper
• Time course of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients presenting with acute coronary syndrome

  2005cites this paper
• In vitro Verhalten der Matrixmetalloproteinase-9 nach hydrostatischer Hochdruckbehandlung

  2005cites this paper
• Prolonged Intake of Dietary Fermented Isoflavone-Rich Soybean Reinforced with Zinc Affects Circulating Bone Biochemical Markers in Aged Individuals

  2005cites this paper
• Relationship between serum β-cryptoxanthin and circulating bone metabolic markers in healthy individuals with the intake of juice (Citrus unshiu) containing β- cryptoxanthin

  2005cites this paper
• Increases in interleukin-6 and matrix metalloproteinase-9 in the infarct-related coronary artery of acute myocardial infarction.

  2004cites this paper
• Effect of Polymyxin B-Immobilized Fiber on Blood Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Levels in Acute Respiratory Distress Syndrome Patients

  2004cites this paper
• Levels of urinary matrix metalloproteinase‐9 (MMP‐9) and renal injuries in patients with type 2 diabetic nephropathy

  2004cites this paper
• Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction.

  2004cites this paper
• Expressions of Matrix Metalloproteinases in Early-Stage Oral Squamous Cell Carcinoma as Predictive Indicators for Tumor Metastases and Prognosis

  2004cites this paper
• Prolonged Intake of Juice (Citrus Unshiu) Reinforced with β-Crypthoxanthin Has an Effect on Circulating Bone Biochemical Markers in Normal Individuals

  2004cites this paper
• Differences between scirrhous and non-scirrhous human gastric carcinomas from the aspect of proMMP-2 activation regulated by TIMP-3

  2004cites this paper
• Rapid, simple, and reliable method for the diagnosis of CAPD peritonitis using the new MMP‐9 test kit

  2004cites this paper
• Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in pigmented villonodular synovitis suggests their potential role for joint destruction.

  2004cites this paper
• Effects of Low‐Density Lipoprotein Apheresis on Plasma Matrix Metalloproteinase‐9 and Serum Tissue Inhibitor of Metalloproteinase‐1 Levels in Diabetic Hemodialysis Patients with Arteriosclerosis Obliterans

  2003cites this paper
• Anti-inflammatory cytokine profile in acute coronary syndromes: behavior of interleukin-10 in association with serum metalloproteinases and proinflammatory cytokines.

  2003cites this paper
• Expression of matrix metalloproteinase‐9 (gelatinase B) in gouty arthritis and stimulation of MMP‐9 by urate crystals in macrophages

  2003cites this paper
• Determining the levels of matrix metalloproteinase-9 in portal and peripheral blood is useful for predicting liver metastasis of colorectal cancer.

  2003cites this paper
• Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study.

  2002cites this paper
• Doxycycline induces apoptosis by way of caspase-3 activation with inhibition of matrix metalloproteinase in human T-lymphoblastic leukemia CCRF-CEM cells.

  2002cites this paper
• Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip.

  2002cites this paper
• Serum-dependent effects of IGF-I and insulin on proliferation and invasion of human first trimester trophoblast cell models

  2002cites this paper
• Changes in the Concentration of Plasma Matrix Metalloproteinases (MMPs) and Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) after Total Joint Replacement in Patients with Arthritis

  2002cites this paper
• Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy.

  2001cites this paper
• Early clinical studies exploring new targets in anticancer treatment

  2001cites this paper
• Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.

  2001cites this paper
• Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis.

  2001cites this paper
• Matrix Metalloproteinases and Tissue lnhibitors of Matrix Metalloproteinases in Sputum from Patients with Bronchial Asthma

  2001cites this paper
• Use of EIA to measure MMPs and TIMPs.

  2001cites this paper
• Biochemical markers in the synovial fluid of glenohumeral joints from patients with rotator cuff tear

  2001cites this paper
• Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand.

  2001cites this paper
• Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in sputum from patients with bronchial asthma.

  2001cites this paper
• Correlations between matrix metalloproteinase-9 and adenosine deaminase isozymes in synovial fluid from patients with rheumatoid arthritis.

  2001cites this paper
• Circulating Matrix Metalloproteinases and Their Inhibitors in Premature Coronary Atherosclerosis

  2001cites this paper
• Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis

  2000cites this paper
• Matrix metalloproteinases in patients with osteoarthritis of the hip

  2000cites this paper
• Expression of elastin-related proteins and matrix metalloproteinases in actinic elastosis of sun-damaged skin

  2000cites this paper
• Elevation of Serum Levels of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-1 and Type IV Collagen, and Plasma Levels of Metalloproteinase-9 in Polycystic Kidney Disease

  2000cites this paper
• Urinary excretion of podocytes in patients with diabetic nephropathy.

  2000cites this paper
• Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1‐matrix metalloproteinase in esophageal squamous cell carcinomas

  2000cites this paper
• Plasma matrix metalloproteinase-9 (gelatinase B) in patients with hepatocellular carcinoma.

  2000cites this paper
• Marked increase of matrix metalloproteinase 9 in cerebrospinal fluid of patients with fungal or tuberculous meningoencephalitis.

  2000cites this paper
• Matrix metalloproteinases and tissue inhibitors of metalloproteinases in joint fluid of the patients with loose artificial hip joints.

  1999cites this paper
• Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and glycosaminoglycans in synovial fluid from patients with rheumatoid arthritis.

  1999cites this paper
• Measurement of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in patients with knee osteoarthritis: comparison with generalized osteoarthritis.

  1999cites this paper
• Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.

  1999influential citation
• Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema.

  1999cites this paper
• Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas.

  1999cites this paper
• Effect of Oral Adsorbent AST-120 on Plasma Metalloproteinase-9 and Serum Tissue Inhibitor of Metalloproteinase-1 Concentrations in Chronic Renal Failure

  1999cites this paper
• Effects of Taurine and Vitamin E on Microalbuminuria, Plasma Metalloproteinase-9, and Serum Type IV Collagen Concentrations in Patients with Diabetic Nephropathy

  1999cites this paper
• Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas.

  1999cites this paper
• Coronary ectasia in familial hypercholesterolemia: histopathologic study regarding matrix metalloproteinases.

  1999cites this paper